The present invention concerns a compound and a pharmaceutical composition for the treatment of inflammations and diseases accompanied by inflammatory processes, in particular inflammatory processes which affect cellular membranes. The present invention also concerns therapeutic methods to ameliorate or prevent the inflammations.According to the invention, at the diseases of mammals a method for the treatment of inflammation or inflammatory-related disorder consists in administering to a mammal in need of such treatment an amount of ribonucleic acid effective to ameliorate the symptoms of inflammation or inflammatory-related disorder in a pharmaceutically acceptable vehicle, carrier, or diluent; an amount of ribonucleic acid effective to stabilize damaged cellular membranes in a pharmaceutically acceptable vehicle, carrier, or diluent is administered to a mammal having damaged cellular membranes; an amount of ribonucleic acid effective to inhibit oxidation of components of cell membranes of the mammal in a pharmaceutically acceptable vehicle, carrier, or diluent is administered to a mammal in need of the treatment; an amount of ribonucleic acid effective to normalize NO-synthetase activity in the mammal in a pharmaceutically acceptable vehicle, carrier, or diluent is administered to a mammal in need of the treatment; an amount of ribonucleic acid effective to inhibit thrombocyte aggregation in a pharmaceutically acceptable vehicle, carrier, or diluent is administered to a mammal in need of the treatment; an amount of ribonucleic acid effective to prevent or treat blood cytopenia in a pharmaceutically acceptable vehicle, carrier, or diluent is administered to a mammal in need of the treatment.According to the method of improving a level of at least one blood indicator, an amount of ribonucleic acid effective to improve a level of at least one blood indicator in an acceptable vehicle, carrier, or diluent is administered to a mammal in need of the treatment; said blood indicator is selected from the respective levels of leukocytes, erythrocytes, thrombocytes, hemoglobin, neutrophils and hematocrits.According to the method of preventing or treating anemia, an effective amount of ribonucleic acid in an acceptable vehicle, carrier, or diluent is administered to a mammal in need of such treatment.According to the method of preventing or treating thrombocytopenia, an effective amount of ribonucleic acid in an acceptable vehicle, carrier, or diluent is administered to a mammal in need of such treatment.According to the method of preventing or treating neutropenia, an effective amount of ribonucleic acid in an acceptable vehicle, carrier, or diluent is administered to a mammal in need of such treatment.In accordance with any of the preceding methods, ribonucleic acid is administered in an amount within a range of from 0.1 mg to 1g per kg weight of a mammal. Said ribonucleic acid is administered in an amount within a range of from 0.1 to 1g. Said ribonucleic acid is obtained from a yeast. Said ribonucleic acid is obtained from a Saccharomyces cerevisiae. Said ribonucleic acid is obtained from a Candida utilis. Said ribonucleic acid has a nitrogen content that is more then 14.5% by weight. Said ribonucleic acid has a phosphorus content that is more then 8.5% by weight. Said ribonucleic acid is administered by an intradermal, hypodermal, oral, intraabdominal, intramuscular, or intravenous route, or is directly administered to a situs of the inflammation or inflammatory-related disorder. Said ribonucleic acid is administered in the form of capsules. Said ribonucleic acid is administered in the form of suppositories. The inflammatory-related disorders are infarct, stroke, arthritis, allergy, pain, fever, swelling.In addition, according to the invention, a pharmaceutical composition for the treatment or the prevention of inflammation or inflammatory-related disorder comprises ribonucleic acid in a pharmaceutically acceptable vehicle, carrier, or diluent. Said ribonucleic acid has a nitrogen content that is more then 14.5% by weight. Said ribonucleic acid has a phosphorus content that is more then 8.5% by weight. A pharmaceutical composition in accordance with any of the variants, characterized in that it is in the form of capsules or suppositories.